Aggressive identification and treatment strategies have led to an overall cure rate for childhood malignancies of greater than 80 percent, but an increasing number of surviving patients are developing therapy-related toxicities later in life.
At the 2019 annual meeting of the Hematology/Oncology Pharmacy Association, Joseph Sciasci, PharmD, and Mary Mably, RPh, reviewed strategies for reducing the impact of late and specific effects of treatment on young adult and adolescent survivors of cancer.